Fig. 1: BoM-1833 cells induce earlier onset of osteolysis and faster tumor growth. | Cell Death & Disease

Fig. 1: BoM-1833 cells induce earlier onset of osteolysis and faster tumor growth.

From: IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis

Fig. 1

a schematic representation of the experimental design. MCF7Luc, MDA-MB-231Luc or BoM-1833Luc cells were injected intrafemorally in female athymic mice (n = 8 for each group). Osteolysis and metastatic tumor growth was monitored by weekly bioluminescence imaging (BLI) and μCT for 4 weeks. Tumor incidence was shown in table below. b Kaplan–Meier survival analysis representing the overall survival of mice with intrafemoral injection of MCF7, MDA-MB-231 or BoM-1833 cells, **p < 0.01, log-rank test. c Representative μCT of longitudinal section femurs (left) and quantification of osteolytic lesion volume (right). d Quantification of bone mineral density (BMD) and trabecular bone volume fraction (BV/TV). e Representative μCT images of reconstructed distal femurs. f Quantification of trabecular number (Tb. N), trabecular separation (Tb. Sp), trabecular thickness (Tb.Th) and cortical thickness (Ct.Th). g ELISA for serum or bone marrow (BM) TGF-β concentrations. h Representative in vivo BLI images and quantification of normalized photon flux and tumor volume size. The data in the figures represent the averages ± SD. Significant differences are indicated as *p < 0.05 or **p < 0.01 paired using Student’s t test unless otherwise specified

Back to article page